Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of conditional share awards.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed is the fair market value of an Ordinary Share at the point of vesting on March 1, 2013, which was £14.55.
Material Changes
The material event reported is the conclusion of the three-year vesting period for awards made under the GlaxoSmithKline Share Value Plan (SVP) in 2010. These awards were conditional on continued employment and vested on March 1, 2013.
Management Commentary and Unusual Items
Management confirmed that the vesting of SVP awards made to individuals subsequently appointed as PDMRs occurred on March 1, 2013. The specific transactions are detailed below:
- Mr R Connor: 1,730 Ordinary Shares vested
- Mr P Thomson: 1,730 Ordinary Shares vested
- Mr C Weber: 4,590 Ordinary Shares vested
- Mrs V Whyte: 1,730 Ordinary Shares vested
The Company and PDMRs were advised of these transactions on March 1, 2013. This notification complies with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares vested for each named PDMR against internal cap tables.
- Confirm the share price of £14.55 on March 1, 2013, to calculate the total value of the vested awards.
- Review the terms of the 2010 Share Value Plan to ensure vesting conditions were met.
- Note that this filing contains no operational or financial performance data for the period.